Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX)

$6.92 -0.01 (-0.14 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$6.92
Today's Range$6.55 - $7.22
52-Week Range$0.88 - $7.36
Volume1.53 million shs
Average Volume2.29 million shs
Market Capitalization$326.05 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660

Debt

Debt-to-Equity RatioN/A
Current Ratio1.20%
Quick Ratio1.20%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.40 per share
Price / Book17.30

Profitability

Trailing EPS($0.84)
Net Income$-14,730,000.00
Net MarginsN/A
Return on Equity-330.42%
Return on Assets-144.29%

Miscellaneous

Employees12
Outstanding Shares47,050,000

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics Inc (NASDAQ:VKTX) announced its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.03. View Viking Therapeutics' Earnings History.

When will Viking Therapeutics make its next earnings announcement?

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 19th 2018. View Earnings Estimates for Viking Therapeutics.

Where is Viking Therapeutics' stock going? Where will Viking Therapeutics' stock price be in 2018?

3 analysts have issued 1-year target prices for Viking Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they anticipate Viking Therapeutics' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Viking Therapeutics.

Are investors shorting Viking Therapeutics?

Viking Therapeutics saw a increase in short interest during the month of January. As of January 12th, there was short interest totalling 1,965,269 shares, an increase of 48.1% from the December 29th total of 1,326,621 shares. Based on an average daily volume of 833,219 shares, the short-interest ratio is presently 2.4 days. Approximately 8.1% of the shares of the company are short sold.

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:

  • Lawson Macartney Ph.D., Chairman of the Board (Age 57)
  • Brian W. Lian Ph.D., President, Chief Executive Officer, Director
  • Michael Morneau, Chief Financial Officer (Age 49)
  • Amy Broidrick, Senior Vice President - Corporate Development
  • Gregory S. Zante CPA, Vice President - Finance and Operations (Age 42)
  • Catherine Lee Kelleher M.D., Vice President - Clinical Development
  • Matthew W. Foehr, Director (Age 44)
  • Charles A. Rowland Jr., Director (Age 59)
  • Matthew Singleton, Independent Director
  • Stephen W. Webster, Independent Director (Age 56)

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Who owns Viking Therapeutics stock?

Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (4.56%), Renaissance Technologies LLC (1.92%), Millennium Management LLC (1.49%), EAM Investors LLC (1.33%), Park West Asset Management LLC (1.28%) and Opaleye Management Inc. (1.06%). View Institutional Ownership Trends for Viking Therapeutics.

Who bought Viking Therapeutics stock? Who is buying Viking Therapeutics stock?

Viking Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, EAM Investors LLC, Renaissance Technologies LLC, Opaleye Management Inc., Park West Asset Management LLC, Iguana Healthcare Management LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Viking Therapeutics.

How do I buy Viking Therapeutics stock?

Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of Viking Therapeutics stock can currently be purchased for approximately $6.92.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $326.05 million. The biotechnology company earns $-14,730,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Viking Therapeutics employs 12 workers across the globe.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (VKTX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Viking Therapeutics (NASDAQ:VKTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$5.67$6.00
Price Target Upside: 13.27% upside76.32% upside104.57% upside541.78% upside

Viking Therapeutics (NASDAQ:VKTX) Consensus Price Target History

Price Target History for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018Maxim GroupReiterated RatingBuy$8.00LowView Rating Details
11/29/2017Roth CapitalSet Price TargetBuy$6.00HighView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy -> Buy$7.00N/AView Rating Details
8/11/2016LaidlawLower Price TargetBuy$20.00 -> $10.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Viking Therapeutics (NASDAQ:VKTX) Earnings History and Estimates Chart

Earnings by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ VKTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/19/2018($0.18)N/AView Earnings Details
11/8/2017Q3 2017($0.19)($0.22)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.21)ViewListenView Earnings Details
5/10/2017Q1 2017($0.17)($0.23)ViewN/AView Earnings Details
3/21/2017Q4 2016($0.20)($0.18)ViewN/AView Earnings Details
11/10/2016Q316($0.21)($0.20)ViewN/AView Earnings Details
8/10/2016Q2($0.20)($0.22)ViewN/AView Earnings Details
5/10/2016Q1($0.45)($0.40)ViewN/AView Earnings Details
3/8/2016Q415($0.44)($0.56)ViewN/AView Earnings Details
11/5/2015($0.37)($0.53)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($1.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Viking Therapeutics (NASDAQ:VKTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.68 EPS

Dividends

Dividend History for Viking Therapeutics (NASDAQ:VKTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Viking Therapeutics (NASDAQ VKTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 11.72%
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ VKTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2016Matthew W FoehrDirectorBuy13,000$1.21$15,730.0039,250View SEC Filing  
4/13/2016Matthew W FoehrDirectorBuy20,000$1.24$24,800.0026,250View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Viking Therapeutics (NASDAQ VKTX) News Headlines

Source:
DateHeadline
Acceleron Pharma (XLRN) versus Viking Therapeutics (VKTX) Head-To-Head AnalysisAcceleron Pharma (XLRN) versus Viking Therapeutics (VKTX) Head-To-Head Analysis
www.americanbankingnews.com - February 17 at 11:18 PM
Zacks: Brokerages Expect Viking Therapeutics Inc (VKTX) to Announce -$0.19 EPSZacks: Brokerages Expect Viking Therapeutics Inc (VKTX) to Announce -$0.19 EPS
www.americanbankingnews.com - February 15 at 9:12 PM
Viking Therapeutics (VKTX) Rating Lowered to Buy at BidaskClubViking Therapeutics (VKTX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - February 15 at 11:18 AM
Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)?Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)?
finance.yahoo.com - February 9 at 9:53 AM
Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs?Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs?
finance.yahoo.com - February 8 at 8:12 AM
Viking Therapeutics (VKTX) Upgraded at BidaskClubViking Therapeutics (VKTX) Upgraded at BidaskClub
www.americanbankingnews.com - February 7 at 11:30 AM
Viking Therapeutics to Present at 2018 BIO CEO & Investor ConferenceViking Therapeutics to Present at 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:41 AM
Zacks: Viking Therapeutics Inc (VKTX) Given $8.38 Average Target Price by AnalystsZacks: Viking Therapeutics Inc (VKTX) Given $8.38 Average Target Price by Analysts
www.americanbankingnews.com - February 2 at 5:12 PM
Viking Therapeutics (VKTX) Stock Rating Reaffirmed by Maxim GroupViking Therapeutics (VKTX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - February 2 at 4:06 PM
Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common StockViking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock
finance.yahoo.com - February 2 at 9:31 AM
Should You Be Concerned About Viking Therapeutics Inc’s (NASDAQ:VKTX) Risks?Should You Be Concerned About Viking Therapeutics Inc’s (NASDAQ:VKTX) Risks?
finance.yahoo.com - February 1 at 3:43 PM
Biotech Viking Therapeutics Could Double From Here -- But Not Without RiskBiotech Viking Therapeutics Could Double From Here -- But Not Without Risk
finance.yahoo.com - January 30 at 3:44 PM
Viking Therapeutics Inc (VKTX) Short Interest Up 48.1% in JanuaryViking Therapeutics Inc (VKTX) Short Interest Up 48.1% in January
www.americanbankingnews.com - January 28 at 1:06 AM
VKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 TrialVKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 Trial
finance.yahoo.com - January 24 at 3:52 PM
Critical Contrast: Viking Therapeutics (VKTX) versus Arrowhead Pharmaceuticals (ARWR)Critical Contrast: Viking Therapeutics (VKTX) versus Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - January 18 at 1:32 PM
Vikings VK2809: A Question Of Safety, Not Efficacy - Seeking AlphaViking's VK2809: A Question Of Safety, Not Efficacy - Seeking Alpha
seekingalpha.com - January 10 at 4:24 PM
Viking Therapeutics to Present at Biotech Showcase 2018Viking Therapeutics to Present at Biotech Showcase 2018
www.prnewswire.com - January 2 at 7:53 AM
What Should We Expect From Viking Therapeutics Inc’s (NASDAQ:VKTX) Earnings Over The Next Few Years?What Should We Expect From Viking Therapeutics Inc’s (NASDAQ:VKTX) Earnings Over The Next Few Years?
finance.yahoo.com - December 30 at 10:13 AM
Zacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 30 at 7:46 AM
Viking Therapeutics: Expecting Further Upside In 2018 - Seeking AlphaViking Therapeutics: Expecting Further Upside In 2018 - Seeking Alpha
seekingalpha.com - December 13 at 10:54 AM
Maxim Group Analysts Give Viking Therapeutics (VKTX) a $8.00 Price TargetMaxim Group Analysts Give Viking Therapeutics (VKTX) a $8.00 Price Target
www.americanbankingnews.com - December 12 at 3:16 PM
Viking Therapeutics Announces Closing of Public Offering of Common StockViking Therapeutics Announces Closing of Public Offering of Common Stock
finance.yahoo.com - December 11 at 4:33 PM
 Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - December 9 at 9:08 PM
Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/ShViking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh
www.streetinsider.com - December 7 at 4:39 PM
Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh - StreetInsider.comViking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh - StreetInsider.com
www.streetinsider.com - December 7 at 10:57 AM
MacroGenics (MGNX) & Viking Therapeutics (VKTX) Head-To-Head ContrastMacroGenics (MGNX) & Viking Therapeutics (VKTX) Head-To-Head Contrast
www.americanbankingnews.com - December 6 at 5:30 PM
Viking Therapeutics (VKTX) Plans Public Offering of Common StockViking Therapeutics (VKTX) Plans Public Offering of Common Stock
www.streetinsider.com - December 6 at 10:50 AM
Viking Therapeutics Announces Proposed Public Offering of Common StockViking Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 5 at 4:21 PM
Viking Therapeutics: Buy The Rumor, Buy The News - Seeking AlphaViking Therapeutics: Buy The Rumor, Buy The News - Seeking Alpha
seekingalpha.com - December 2 at 8:49 AM
ValuEngine Downgrades Viking Therapeutics (VKTX) to SellValuEngine Downgrades Viking Therapeutics (VKTX) to Sell
www.americanbankingnews.com - December 2 at 12:40 AM
Roth Capital Analysts Give Viking Therapeutics (VKTX) a $6.00 Price TargetRoth Capital Analysts Give Viking Therapeutics (VKTX) a $6.00 Price Target
www.americanbankingnews.com - November 30 at 9:54 AM
Zacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 30 at 1:28 AM
Viking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatmentViking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatment
www.marketwatch.com - November 29 at 10:39 AM
Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211
www.streetinsider.com - November 29 at 10:39 AM
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip FractureViking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
www.prnewswire.com - November 29 at 10:39 AM
VKTX: Positive Results From Phase 2 Study of VK5211 in Hip FractureVKTX: Positive Results From Phase 2 Study of VK5211 in Hip Fracture
finance.yahoo.com - November 29 at 10:39 AM
Contrasting Viking Therapeutics (VKTX) & Its PeersContrasting Viking Therapeutics (VKTX) & Its Peers
www.americanbankingnews.com - November 28 at 3:06 PM
Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211 - StreetInsider.comViking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211 - StreetInsider.com
www.streetinsider.com - November 28 at 11:36 AM
Viking Therapeutics (VKTX) PT Set at $8.00 by Maxim GroupViking Therapeutics (VKTX) PT Set at $8.00 by Maxim Group
www.americanbankingnews.com - November 28 at 11:20 AM
Analyzing Viking Therapeutics (VKTX) and Its PeersAnalyzing Viking Therapeutics (VKTX) and Its Peers
www.americanbankingnews.com - November 27 at 3:56 PM
Head-To-Head Comparison: Viking Therapeutics (VKTX) and Its RivalsHead-To-Head Comparison: Viking Therapeutics (VKTX) and Its Rivals
www.americanbankingnews.com - November 24 at 1:24 AM
Viking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth CapitalViking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth Capital
www.americanbankingnews.com - November 21 at 10:33 AM
Viking Therapeutics (VKTX) vs. Its Rivals Head-To-Head AnalysisViking Therapeutics (VKTX) vs. Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - November 14 at 9:48 AM
Viking Therapeutics (VKTX) Buy Rating Reaffirmed at HC WainwrightViking Therapeutics' (VKTX) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 12 at 1:10 PM
VKTX: Data From Phase 2 Trial of VK5211 to be Reported SoonVKTX: Data From Phase 2 Trial of VK5211 to be Reported Soon
finance.yahoo.com - November 12 at 1:10 PM
Viking Therapeutics, Inc. (VKTX) Announces Quarterly  Earnings ResultsViking Therapeutics, Inc. (VKTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 5:36 PM
Viking Therapeutics (VKTX) CEO Brian Lian on Q3 2017 Results ... - Seeking AlphaViking Therapeutics' (VKTX) CEO Brian Lian on Q3 2017 Results ... - Seeking Alpha
seekingalpha.com - November 9 at 9:32 AM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateViking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 9:32 AM
Analyzing Viking Therapeutics (VKTX) and The CompetitionAnalyzing Viking Therapeutics (VKTX) and The Competition
www.americanbankingnews.com - November 8 at 9:34 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 - PR Newswire (press release)Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 - PR Newswire (press release)
www.prnewswire.com - November 1 at 10:25 AM

SEC Filings

Viking Therapeutics (NASDAQ:VKTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Viking Therapeutics (NASDAQ:VKTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Viking Therapeutics (NASDAQ VKTX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.